United States Biotechnology & Medical Research

Catalyst Pharmaceuticals Inc (CPRX)

Track

The most recent insider trading activity occurred on December 12, 2025, with multiple SELL and PROPOSED_SALE transactions by Molly Harper. Prior to that, Jeffrey Del Carmen and Brian Elsbernd engaged in SELL and PROPOSED_SALE transactions in November and September 2025. David S. Tierney also had SELL and PROPOSED_SALE transactions in August 2025.
Stock chart
Ticker: CPRX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Harper Molly
4 sales — total 1,243,849 USD
Sale 12 Dec 2025
Value US$517,603.17 | Price 275.42 | Shares 63,325
Sale 12 Dec 2025
Value US$1,310,416.40 | Price 21.87 | Shares 94,777
Sale 12 Dec 2025
Value US$360,195.35 | Price 23.20 | Shares 15,527
Proposed sale 12 Dec 2025
Value US$621,929.15 | Price 23.25 | Shares 26,746
Sale 26 Nov 2025
Value US$3,466,387.87 | Price 261.70 | Shares 97,089
Proposed sale 26 Nov 2025
Value US$2,312,202.57 | Price 236.94 | Shares 74,604
Proposed sale 12 Nov 2025
Value US$907,933.96 | Price 22.70 | Shares 40,000
Sale 8 Sep 2025
Value US$609,000.00 | Price 20.30 | Shares 30,000
Proposed sale 8 Sep 2025
Value US$609,035.49 | Price 20.30 | Shares 30,000
Sale 4 Sep 2025
Value US$585,600.00 | Price 19.52 | Shares 30,000
Proposed sale 4 Sep 2025
Value US$585,640.54 | Price 19.52 | Shares 30,000
Sale 3 Sep 2025
Value US$401,600.00 | Price 20.08 | Shares 20,000
Proposed sale 3 Sep 2025
Value US$401,514.10 | Price 20.08 | Shares 20,000
Sale 27 Aug 2025
Value US$525,200.00 | Price 20.20 | Shares 26,000
Proposed sale 27 Aug 2025
Value US$525,087.81 | Price 20.20 | Shares 26,000
Sale 26 Aug 2025
Value US$473,641.40 | Price 20.62 | Shares 22,970
Proposed sale 26 Aug 2025
Value US$473,641.40 | Price 20.62 | Shares 22,970
Sale 26 Aug 2025
Value US$2,332,200.00 | Price 20.28 | Shares 115,000
Proposed sale 26 Aug 2025
Value US$2,332,370.02 | Price 20.28 | Shares 115,000
Sale 11 Jun 2025
Value US$42,272.00 | Price 26.42 | Shares 1,600
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-16 2025-12-12 S Sale
2.5
Harper Molly
Non-Executive Director
63,325 -4.2%
275.42
US$517,603 		63,325 -4.2% 275.42 US$517,603
2025-12-16 2025-12-12 S Sale
2.5
Harper Molly
Non-Executive Director
94,777 +4.4%
21.87
US$1,310,416 		94,777 +4.4% 21.87 US$1,310,416
2025-12-16 2025-12-12 S Sale
2.5
Harper Molly
Non-Executive Director
65,359 +5.0%
146.38
US$2,691,043 		65,359 +5.0% 146.38 US$2,691,043
2025-12-12 2025-12-12 PrS Proposed sale
2.5
Harper Molly

Director

Non-Executive Director
26,746
23.25
US$621,929 		26,746 23.25 US$621,929
2025-11-28 2025-11-26 S Sale
2.9
Del Carmen Jeffrey

Chief Commercial Officer

Officer
10,983 -73.5%
23.33
US$256,244 		10,983 -73.5% 23.33 US$256,244
2025-11-26 2025-11-26 PrS Proposed sale
2.9
Del Carmen Jeffrey

Officer

Officer
10,983
23.33
US$256,247 		10,983 23.33 US$256,247
2025-11-12 2025-11-12 PrS Proposed sale
2.7
Elsbernd Brian

Officer

Officer
40,000
22.70
US$907,934 		40,000 22.70 US$907,934
2025-09-10 2025-09-08 S Sale
2.7
Elsbernd Brian

Chief Compliance/Legal Officer

Officer
30,000 -10.0%
20.30
US$609,000 		30,000 -10.0% 20.30 US$609,000
2025-09-08 2025-09-08 PrS Proposed sale
2.7
Elsbernd Brian

Officer

Officer
30,000
20.30
US$609,035 		30,000 20.30 US$609,035
2025-09-05 2025-09-04 S Sale
2.7
Elsbernd Brian

Chief Compliance/Legal Officer

Officer
30,000 -13.7%
19.52
US$585,600 		30,000 -13.7% 19.52 US$585,600
2025-09-04 2025-09-04 PrS Proposed sale
2.7
Elsbernd Brian

Officer

Officer
30,000
19.52
US$585,641 		30,000 19.52 US$585,641
2025-09-05 2025-09-03 S Sale
2.7
Elsbernd Brian

Chief Compliance/Legal Officer

Officer
20,000 -9.6%
20.08
US$401,600 		20,000 -9.6% 20.08 US$401,600
2025-09-03 2025-09-03 PrS Proposed sale
2.7
Elsbernd Brian

Officer

Officer
20,000
20.08
US$401,514 		20,000 20.08 US$401,514
2025-08-28 2025-08-27 S Sale
2.9
Tierney David S
Non-Executive Director
26,000 -6.4%
20.20
US$525,200 		26,000 -6.4% 20.20 US$525,200
2025-08-27 2025-08-27 PrS Proposed sale
2.9
Tierney David S

Director

Non-Executive Director
26,000
20.20
US$525,088 		26,000 20.20 US$525,088
2025-08-28 2025-08-26 S Sale
2.2
Daly Richard J

President and CEO

Executive Director
22,970 -9.2%
20.62
US$473,641 		22,970 -9.2% 20.62 US$473,641
2025-08-28 2025-08-26 S Sale
2.7
Miller Steve

Chief Op. & Scientific Officer

Officer
115,000 -10.8%
20.28
US$2,332,200 		115,000 -10.8% 20.28 US$2,332,200
2025-08-26 2025-08-26 PrS Proposed sale
2.7
Miller Steve

Officer

Officer
115,000
20.28
US$2,332,370 		115,000 20.28 US$2,332,370
2025-08-26 2025-08-26 PrS Proposed sale
2.2
Daly Richard J

Officer; Director

Executive Director
22,970
20.62
US$473,641 		22,970 20.62 US$473,641
2025-06-12 2025-06-11 S Sale
2.7
Sundaram Preethi

Chief Strategy Officer

Officer
1,600 -3.7%
26.42
US$42,272 		1,600 -3.7% 26.42 US$42,272
Explore more

More insider trading research around Catalyst Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America